Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients

Leukemia volume 20, pages 542–545 (2006)Cite this article

Autologous stem cell transplantation (ASCT) has become the standard of care for young patients diagnosed with multiple myeloma (MM). Nevertheless, the median duration of response after ASCT does not exceed 3 years, and almost all patients ultimately relapse. By contrast, allogeneic transplantation has led to a long-term disease-free survival in a fraction of MM patients.1 Unfortunately, allogeneic transplantation has been associated with a high transplant-related mortality (TRM), ranging from 30 to 50% in the first 180 days.2 In order to overcome this high mortality, new approaches using nonmyeloablative or reduced-intensity conditioning (RIC) regimens have been designed, in an effort to reduce the toxicity associated with the high doses of chemotherapy, but maintaining the graft-versus-myeloma (GVM) effect.3 Nevertheless, the low TRM observed using this approach is partially overwhelmed by the high relapse rate reported among high-risk patients, such as those carrying chromosome abnormalities (del 13) or those relapsing after a previous ASCT.4, 5 On the other hand, the European Blood and Marrow Transplantation (EBMT) study group has reported a decrease in TRM from 46 to 33% in MM patients undergoing myeloablative allogeneic transplantation prior to or after 1993.6 In addition, new treatment strategies based on thalidomide/IMIDs and proteasome inhibitors are demonstrating a high efficacy in terms of disease control in refractory MM patients. Thus, with the new therapeutic armamentarium available for MM patients, results on the long-term outcome are required in order to better define the role of allo-RIC in the management of MM.

In the current study, we analyzed the efficacy of allo-RIC in a series of 70 MM patients enrolled in the Spanish allo-RIC program between May 1999 and August 2004. Median age was 54 years (30–66 years). All patients received peripheral blood progenitor cells (PBPC) from an MRD, and all but six had received a previous autologous transplant (ASCT). In total, 15 patients were included in a sequential ASCT-allo-RIC approach. Overall, 33 patients had either relapsed (n=29) or did not respond (n=4) to prior ASCT. Disease status at transplant was complete remission (CR) in 5 (7.1%) patients, partial response (PR) in 37 (52.9%) patients, stable disease (SD) in 7 (10%) patients and progressive disease (PD) in 21 (30%) patients. All but three patients were conditioned with fludarabine 30 mg/m2 intravenously (i.v.) on days −8 to −4 followed by melphalan 70 mg/m2 i.v. on days −3 and −2 (n=39) or on day −2 (n=28). Two patients received busulphan 10 mg/m2 instead of melphalan and one patient received 200 cGy TBI. Standard graft-versus-host disease (GVHD) prophylaxis consisted of conventional doses of cyclosporine A (CsA) plus three (n=18) or four doses of MTX (n=50). Two patients received CsA plus ATG.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli RM et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000; 18: 2273–2281.

    Article  CAS  Google Scholar 

  2. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M et al. Allogeneic bone marrow transplantation in multiple myeloma: European Group for Bone Marrow Transplantation. N Engl J Med 1991; 325: 1267–1273.

    Article  CAS  Google Scholar 

  3. Perez-Simon JA, Martino R, Alegre A, Brunet S, Urbano A, Caballero MD et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 2003; 121: 104–108.

    Article  Google Scholar 

  4. Kröger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A et al. Deletion of chromosome 13q14 detected by fluorescence in situ hybridization as prognostic factor following allogeneic dose reduce stem cell transplantation in patients with multiple myeloma. Blood 2004; 103: 4056–4061.

    Article  Google Scholar 

  5. Crawley C, Lalancete M, Szydlo R, Gilleece M, Peggs K, Mackinnon S et al. Outcomes for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the chronic leukemia working party of the EBMT. Blood 2005; 105: 4532–4539.

    Article  CAS  Google Scholar 

  6. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Bjorkstrand B et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209–216.

    Article  CAS  Google Scholar 

  7. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl I . Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005; 105: 317–323.

    Article  CAS  Google Scholar 

  8. Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A et al. Influence of timing allogeneic stem cell transplantation after dose-reduced melphalan/fludarabine conditioning in multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 698–708.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital Clínico Universitario, Salamanca, Spain

    J A Pérez-Simón, D Caballero, C Cañizo, L Vazquez & J F San Miguel

  2. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    A Sureda, R Martino, S Brunet, A García & J Sierra

  3. Hospital Clinic i Provincial, Barcelona, Spain

    F Fernández-Aviles & L Rosiñol

  4. Hospital Son Dureta, Barcelona, Spain

    A Sampol

  5. Hospital Puerta de Hierro, Madrid, Spain

    J R Cabrera

  6. Instituto Catalán de Oncología, Barcelona, Spain

    J Petit

  7. Fundacion Jimenez Diaz, Madrid, Spain

    J F Tomás

  8. Hospital Morales Meseguer, Murcia, Spain

    J M Moraleda

  9. Hospital de la Princesa, Madrid, Spain

    A Alegre

  10. Hospital 12 de Octubre, Madrid, Spain

    J Lahuerta

  11. Hospital Gregorio Marañón, Madrid, Spain

    J L Díez-Martín

  12. Hospital de Jerez, Jeréz, Spain

    A León

Authors
  1. J A Pérez-Simón
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Sureda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Fernández-Aviles
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Sampol
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J R Cabrera
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Caballero
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Petit
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J F Tomás
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J M Moraleda
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Alegre
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C Cañizo
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. S Brunet
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. L Rosiñol
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. J Lahuerta
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. J L Díez-Martín
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. A León
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. A García
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. L Vazquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. J Sierra
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. J F San Miguel
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the GEM (Grupo Español de Mieloma)

Corresponding author

Correspondence to J A Pérez-Simón.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pérez-Simón, J., Sureda, A., Fernández-Aviles, F. et al. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia 20, 542–545 (2006). https://doi.org/10.1038/sj.leu.2404085

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404085

This article is cited by

Search

Advanced search

Quick links